News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Leslie Zacks Joins Arbor Pharmaceuticals as General Counsel and Chief Compliance Officer


2/21/2012 12:01:53 PM

ATLANTA, Feb. 21, 2012 /PRNewswire/ -- Arbor Pharmaceuticals, a specialty pharmaceutical company based in Atlanta, GA, announced today that Leslie Zacks has joined the company as General Counsel and Chief Compliance Officer. Mr. Zacks has a distinguished legal career and most recently held positions of increasing responsibility at Shionogi Pharma, Inc. (previously Sciele Pharma). While at Shionogi, Leslie built the company's legal department and served on the company's executive leadership team where he was responsible for all legal, IP and compliance functions.

Mr. Zacks has been a practicing attorney in Atlanta, Georgia since 1994. He was the Executive Vice President, General Counsel and Chief Compliance Officer at Shionogi Pharma, Inc. from 2004-2010. From 2002 to 2004, Mr. Zacks worked at Hunton & Williams, LLP where he was a partner in the Intellectual Property Litigation department. Mr. Zacks is a registered patent attorney who has held associate positions at Powell, Goldstein, Frazer & Murphy, LLP (now Bryan Cave, LLP) and at Carlock, Copeland and Stair, LLP. Mr. Zacks holds a J.D. and a B.A. in English from the University of Florida.

Ed Schutter, President and CEO of Arbor, commented, "We are pleased that Leslie has joined Arbor in this significant role for the company. Leslie has deep experience in patent law, mergers and acquisitions, compliance, and in many other key areas critical to Arbor as we continue our significant growth."

Mr. Zacks added, "I am pleased to be joining Arbor at this important point in the company's growth. The company is well positioned to execute on its plan, and I look forward to building on Arbor's success in my new role."

About Arbor Pharmaceuticals, Inc.

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular and pediatric markets. The company intends to become a leading specialty pharmaceutical company by actively licensing, developing and commercializing late-stage products for specialty focused conditions. Arbor currently markets multiple NDA and ANDA approved products with several more in development.

For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

SOURCE Arbor Pharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES